|
Germline BRCA1and BRCA2 mutations in patients with HER2-negative metastatic breast cancer (mBC) treated with first-line chemotherapy: Data from the German PRAEGNANT registry. |
|
|
Honoraria - Amgen; AstraZeneca; Celgene; Daiichi Sankyo; Eisai; Hexal; Merck Sharp & Dohme; Myelo Therapeutics GmbH; Novartis; Pfizer; Puma Biotechnology; Roche; Teva |
Consulting or Advisory Role - Amgen; AstraZeneca; Celgene; Daiichi Sankyo; Eisai; Hexal; Merck Sharp & Dohme; Myelo Therapeutics GmbH; Novartis; Pfizer; Puma Biotechnology; Roche; Teva |
Research Funding - BioNTech (Inst); Novartis (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - AstraZeneca; Genomic Health; Novartis |
|
|
Honoraria - AstraZeneca; Janssen Diagnostics; Lilly; Novartis; Pfizer; Roche |
Consulting or Advisory Role - AstraZeneca; Lilly; Menarini Silicon Biosystems; Novartis; Pfizer; Roche |
Research Funding - Amgen (Inst); Janssen Diagnostics; Lilly (Inst); Menarini Silicon Biosystems; Novartis (Inst); Pfizer (Inst); Roche (Inst) |
|
|
Honoraria - Novartis; Pfizer; Roche Pharma AG |
Travel, Accommodations, Expenses - Novartis; Pfizer; Roche Pharma AG |
|
|
No Relationships to Disclose |
|
|
Honoraria - AstraZeneca; Lilly; Novartis; Pfizer; Roche; Tesaro; Tesaro; Teva |
Consulting or Advisory Role - Lilly; Novartis; Pfizer; Roche; Tesaro |
Speakers' Bureau - AstraZeneca; Celgene; Lilly; Pfizer; Roche; Teva |
Travel, Accommodations, Expenses - Celgene; Pfizer; Teva |
|
|
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Cellex; Chugai Pharma; Gilead Sciences; Hexal; Ipsen; Janssen; Merck; MSD; Novartis; RIEMSER; Roche; Tesaro; Teva |
|
|
Honoraria - AstraZeneca; Eisai; Genomic Health; Hexal; Lilly; Novartis; Pfizer; Roche Pharma AG |
Consulting or Advisory Role - AstraZeneca; Eisai; Genomic Health; Grunenthal; Lilly; MSD Oncology; Novartis; Pfizer; Roche Pharma AG; Tesaro |
Speakers' Bureau - AstraZeneca; Lilly; MSD Oncology; Novartis; Pfizer; Roche Pharma AG |
Research Funding - Discovering Hands (Inst) |
Travel, Accommodations, Expenses - Pfizer; Roche Pharma AG |
Other Relationship - Medac |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - AstraZeneca; Celgene; Novartis |
|
|
Honoraria - Amgen; AstraZeneca; Celgene; Daiichi Sankyo; Eisai; Novartis; Pierre Fabre; Roche/Genentech; Teva |
Consulting or Advisory Role - Amgen; Daiichi Sankyo; Eisai; Eisai; Genomic Health; Nektar; Pfizer; Pierre Fabre |
Travel, Accommodations, Expenses - Pfizer; Roche/Genentech |
|
|
Stock and Other Ownership Interests - Phaon Scientific; Theraclion |
Honoraria - Amgen; AstraZeneca; Carl Zeiss Meditec; Genomic Health; Novartis; Pfizer; Roche; SurgVision; Theraclion |
Consulting or Advisory Role - SurgVision |
Travel, Accommodations, Expenses - Amgen; Carl Zeiss Meditec; Daiichi Sankyo; Genomic Health; LIV Pharma; Novartis; Pfizer; Roche; Tesaro |
|
|
Consulting or Advisory Role - Amgen; AstraZeneca; Celgene; Daiichi Sankyo; Novartis; Pfizer; Roche |
Research Funding - Novartis |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Roche, Novartis, Pfizer |
Research Funding - Novartis, Roche, Pfizer (Inst) |
Travel, Accommodations, Expenses - Roche, Novartis, Pfizer |
|
|
Honoraria - AstraZeneca; Celgene; Lilly; MSD Oncology; Novartis; Pfizer; Roche Pharma AG; Tesaro |
Research Funding - Abbvie; Celgene (Inst); Molecular Partners; Roche Pharma AG (Inst) |
Expert Testimony - AstraZeneca; Roche |
Travel, Accommodations, Expenses - Celgene; Roche |
|
|
Consulting or Advisory Role - AstraZeneca |
|
Travel, Accommodations, Expenses - GRAIL; Qiagen |
Other Relationship - Ambry Genetics |